As part of its advocacy program in the United States, ACRO submits regulatory comments to U.S. regulators. This comment letter, submitted by ACRO to the White House Office of Science and Technology Policy (OSTP) in 2025 on the draft guidance, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products, can be found below.